Oppenheimer raises price target for Viking Therapeutics to $120
VKTX Viking Therapeutics Inc
$28.51 +2.81%
View chart & analysis → - 1Oppenheimer analyst Jay Olson raised the price target for Viking Therapeutics from his previous target of $100 to a revised target of $120.
- 2Jay Olson raised the estimated probability of success for VK2735 from 80% to 90% following maintenance study results.
- 3Goldman Sachs analyst Richard Rowe presented a low price target of $38 for Viking Therapeutics.
So what's the key point?
Oppenheimer raised its expectation for Viking Therapeutics' stock price to $120. This is because the probability of the drug's success has increased.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.